THE DIMECANNABIS
← Answers
Answers

What Determines Which Cannabinoids Actually Reach the Market?

AI-Generated · Written by Isaac Burner, AI analyst for The Dime. Sourced from our episodes and reviewed before publishing.
Isaac BurnerOctober 20, 2026484 words
Medical & ResearchCultivation & ExtractionLitigation & Legal
Short answer

Price, not therapeutic promise, decides which cannabinoids become real products. Shane Johnson of BayMedica says adoption tends to take off once a cannabinoid drops below roughly $3,000 to $5,000 per kilogram, and patent strategy shapes whether a compound is made plant-identical or as a novel analog.

The science of discovering a new cannabinoid is not the bottleneck. The economics of making it cheap enough to sell, and the legal strategy around who owns the process, are what actually decide whether a compound shows up on a shelf.

Price has to clear a specific threshold before anyone bothers

Shane Johnson of BayMedica, a subsidiary of InMed Pharmaceuticals, laid out the math in How Minor Cannabinoids are Made: Synthetic vs Biosynthetic ft. Shane Johnson. CBD isolate went from around $60,000 a kilogram down to around $300. Johnson says real market adoption of a cannabinoid tends to require pricing below roughly $3,000 to $5,000 a kilogram, because above that the resulting product premium is more than consumers will pay. That single number explains a lot about why some rare cannabinoids stay lab curiosities while others, like CBN and CBG, end up in mainstream formulations. Johnson's own line on the direction of travel: "Price in this industry only moves in one direction: down."

This is also why biosynthesis and chemical synthesis exist at all. The plant makes compounds like THCV in such small quantities, alongside everything else, that extracting them in pure form at scale is not commercially practical. Johnson explained that BayMedica engineers yeast or uses chemical synthesis to produce plant-identical cannabinoids precisely because the plant can't deliver volume and purity together at a workable cost. He also pointed out that THCV is harder to manufacture in its Delta-9 form than CBC, because chemical synthesis naturally favors the more stable Delta-8 configuration, and BayMedica has gotten to around 98% Delta-9 THCV purity.

Patent strategy decides whether a company builds plant-identical or goes novel

The other lever is intellectual property. Johnson described InMed's pharmaceutical work on plant-identical CBN, including a completed phase two trial in epidermolysis bullosa, a rare disease. But he said the company is now putting more pharmaceutical development focus into novel analogs: taking a molecule like CBN or CBD and modifying its side chain, say adding a chloride instead of just carbons. Some of those variants may be more potent than the naturally occurring cannabinoid, and critically, they can be patented. Johnson noted it's also easier to protect because it's harder for someone else to replicate the same purity profile. Plant-identical cannabinoids are useful and often what consumer brands want, but they don't generate the same IP moat that a novel analog does.

What this means for an operator

If you're formulating with minor cannabinoids, the question is not whether the science supports an effect. It's whether the input cost lets you price the finished product within reach of a normal consumer, and whether your supplier is building something defensible or something anyone can replicate once the patent landscape settles. A cannabinoid with great anecdotal results and a $10,000/kg price tag is not a product. It's a lab sample waiting for someone to solve the cost problem first.

Where this comes from
How Minor Cannabinoids are Made: Synthetic vs Biosynthetic ft. Shane Johnson
Ep. 203 · Shane Johnson · May 16, 2024

Related questions

Why do some minor cannabinoids stay expensive longer than others?

Johnson said manufacturing difficulty varies by cannabinoid: THCV is harder to produce in pure Delta-9 form than CBC because chemical synthesis naturally favors the more stable Delta-8 configuration, which keeps THCV costlier to make at high purity.

Does a novel cannabinoid analog need the same clinical testing as a plant compound?

The transcript doesn't specify a different regulatory track, but Johnson described InMed as pursuing novel analogs through pharmaceutical development, including the kind of trial work already done on plant-identical CBN for epidermolysis bullosa.

Is biosynthesis cheaper than extracting from the plant?

Johnson framed biosynthesis and synthesis as solutions to a practical problem: the plant produces rare cannabinoids like THCV in such small amounts that pure extraction at scale isn't practical, which is why engineered yeast and chemical synthesis exist as alternatives.